MABT was founded in 2011 with the mission of eradicating terrible infectious diseases using a novel, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. This revolutionary type of immune system-based therapy is called “immunotherapy”.
Fundamentally, we are a speciality pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, primarily targeting the growing antibiotic resistance problem. MABT’s pioneering new Rabies therapy is the first to have received a valuable regulatory incentive called Orphan Drug Designation. Orphan Drug Designation offers one strategy for ensuring a more rapid, efficient pathway to FDA approval.